Sarcoma News and Research

RSS

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

31 Aug 2009

Childhood cancer risk rises with mother's age

Research from the Masonic Cancer Center, University of Minnesota indicates that a baby born to an older mother may have a slightly increased risk for many of the cancers that occur during childhood.

14 Jul 2009

Caucasians more likely to develop Ewing's sarcoma than other races

The largest analysis of its kind has found that Caucasians are much more likely that people in other racial/ethnic groups to develop a rare bone and soft tissue cancer called Ewing's sarcoma. In addition, among Caucasians with this cancer, men are more likely to die than women.

22 Jun 2009

Research uncovers clues to the development of cancers in AIDS patients

In a series of recently-published articles, a research team from the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center has uncovered clues to the development of cancers in AIDS patients.

17 Jun 2009

Antiretroviral therapy earlier yields better clinical outcomes

A clinical trial has demonstrated that HIV-infected adults in a resource-limited setting are more likely to survive if they start antiretroviral therapy (ART) before their immune systems are severely compromised.

9 Jun 2009

NIH grants will strengthen fight against HIV/AIDS-tuberculosis

The Fogarty International Center of the National Institutes of Health today announced it will award $11.75 million over five years in grants to institutions to strengthen the fight against HIV/AIDS and tuberculosis in Haiti, Uganda and China and establish a new program in Tanzania.

16 Apr 2009

PET/CT imaging shows if single cycle of chemo is working

Oncologists often have to wait months before they can determine whether a treatment is working.

14 Apr 2009

A second MND gene mutation in one year signifies rapid research progress

A collaborative research project involving Professor Christopher Shaw of the Institute of Psychiatry, King's College London (KCL), Dr Tom Kwiatkowski at Massachusetts General Hospital (MGH) and Professor Robert H Brown at University of Massachusetts, has revealed that mutations in a gene called FUS (fused in sarcoma) cause familial Motor Neuron Disease (also known as Amyotrophic Lateral Sclerosis).

26 Feb 2009

Researchers find genes that fuse in cancer

Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other.

12 Jan 2009

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

14 Dec 2008

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008.

20 Nov 2008

Ortho Biotech submits NDA for Trabectedin in relapsed ovarian cancer

Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).

20 Nov 2008

REOLYSIN shown to benefit some sarcoma patients

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

19 Nov 2008

Risk of non-AIDS cancer higher for individuals infected with HIV

The risk of non-AIDS cancer is higher for individuals infected with HIV than for the general population, according to a meta-analysis presented here at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.

18 Nov 2008

Ewing sarcoma treatment ineffective, despite promising laboratory data

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults.

10 Nov 2008

FDA grants orphan drug status to new 'Trojan Horse' like Ewing's Sarcoma drug

The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation's unique drug product for children with Ewing's Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers in private industry and at two universities.

20 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008